

**Associate Professor Michael Beard**

**Grants through ACH<sup>2</sup> have funded a project titled Phase II of Laboratory-Based Platforms To Manage Patients Who Develop Antiviral Drug-Resistance To Direct-Acting Antiviral Agents (DAAs).**

Direct acting antiviral agents (DAAs) targeted against the HCV NS3/4A, NS5A and NS5B viral proteins are emerging to combat chronic hepatitis C. The first to the clinic will be the NS3/4A protease inhibitors however the ability of HCV to mutate to high levels means that resistant will rapidly emerge. We have developed laboratory based assays that allows for tracking of the emergence of these resistance mutations during therapy, to determine their effect on viral replication develop a clinically useful data-base-derived clinical management algorithm in order to predict the next and appropriate therapeutic option. The ultimate outcome of this platform will be optimised patient care for persons with chronic hepatitis C.